ValuEngine upgraded shares of Intrexon (NYSE:XON) from a sell rating to a hold rating in a report issued on Monday morning.

A number of other analysts also recently weighed in on the stock. Stifel Nicolaus initiated coverage on shares of Intrexon in a research report on Tuesday, July 17th. They set a buy rating and a $72.00 price target for the company. Zacks Investment Research raised shares of Intrexon from a hold rating to a buy rating and set a $16.00 price target for the company in a research report on Thursday, August 16th. Finally, Bank of America downgraded shares of Intrexon from a neutral rating to an underperform rating and set a $12.00 price target for the company. in a research report on Monday, July 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $33.14.

XON stock opened at $17.56 on Monday. Intrexon has a twelve month low of $10.26 and a twelve month high of $20.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.78 and a quick ratio of 1.53. The company has a market cap of $2.47 billion, a PE ratio of -18.79 and a beta of 1.09.

Intrexon (NYSE:XON) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The company had revenue of $45.30 million for the quarter, compared to analyst estimates of $51.70 million. During the same period in the previous year, the business posted ($0.16) EPS. analysts anticipate that Intrexon will post -0.79 EPS for the current year.

In related news, insider Helen Sabzevari sold 8,402 shares of the firm’s stock in a transaction on Wednesday, July 18th. The stock was sold at an average price of $14.54, for a total transaction of $122,165.08. Following the transaction, the insider now directly owns 25,000 shares in the company, valued at $363,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Randal J. Kirk acquired 7,479,431 shares of Intrexon stock in a transaction that occurred on Tuesday, July 3rd. The shares were purchased at an average price of $13.37 per share, for a total transaction of $99,999,992.47. The disclosure for this purchase can be found here. Company insiders own 48.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Third Security LLC lifted its stake in Intrexon by 0.3% during the second quarter. Third Security LLC now owns 59,309,806 shares of the biotechnology company’s stock worth $826,779,000 after purchasing an additional 177,101 shares during the last quarter. BlackRock Inc. lifted its stake in Intrexon by 76.8% in the second quarter. BlackRock Inc. now owns 4,647,554 shares of the biotechnology company’s stock valued at $64,788,000 after buying an additional 2,019,142 shares during the last quarter. Morgan Stanley lifted its stake in Intrexon by 6.7% in the second quarter. Morgan Stanley now owns 3,118,444 shares of the biotechnology company’s stock valued at $43,470,000 after buying an additional 196,999 shares during the last quarter. Northern Trust Corp lifted its stake in Intrexon by 123.1% in the second quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock valued at $12,791,000 after buying an additional 506,186 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Intrexon by 31.3% in the second quarter. Bank of America Corp DE now owns 738,264 shares of the biotechnology company’s stock valued at $10,291,000 after buying an additional 176,105 shares during the last quarter. Hedge funds and other institutional investors own 84.92% of the company’s stock.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Read More: Stop Order

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.